Publication at Second Faculty of Medicine |
2022
Abstract
Acute lymphoblastic leukemia (ALL) in children is a disease with a good chance of cure on current modern treatment protocols. Nevertheless, 10-15 % of children experience a relapse of the disease, some of them are already resistant to chemotherapy and require the use of additional treatment modalities.
Of these new treatments, immunotherapy and other targeted drugs are already being used in current clinical practice, which have a very good effect even in significantly pre-treated patients and are gradually changing the concept of ALL treatment.